Le Lézard
Classified in: Ebola virus, Health
Subjects: CCA, ACC

Essity - Interim Report Q3 2017

STOCKHOLM, Oct. 26, 2017 /PRNewswire/ --


(compared with the corresponding period a year ago)

[1] Indicative earnings per share on the assumption that the number of issued shares in Essity as of September 30, 2016 corresponded to the number of issued shares in Essity on September 30, 2017 (702.3 million).


The Group's net sales for the third quarter of 2017 increased 7.7% compared with the corresponding period a year ago. Organic sales increased by 1.8%, of which volume accounted for 2.2% and price/mix for -0.4%. In emerging markets, which represented 34% of net sales, organic sales rose by 6.8%, while in mature markets organic sales declined by 0.8%. Organic sales were negatively impacted by a lower market growth due to such factors as price pressure and as a consequence of Essity's decision to discontinue certain underperforming market positions and contracts as part of the company's focus on profitable growth for increased value creation. During the quarter, 13 innovations were launched that strengthened Essity's customer and consumer offering in all categories.

The Group's adjusted EBITA in the third quarter of 2017 increased by 10% compared with the corresponding period a year ago. Excluding currency translation effects and the acquisition of BSN medical, the adjusted EBITA declined by 1% compared with the corresponding period a year ago. The decline was mainly the result of higher raw material costs and lower prices. Higher volumes, cost savings and other measures to improve profitability had a positive impact on earnings.

The Group's adjusted EBITA margin increased 0.3 percentage points to 12.6%. The adjusted return on capital employed was 13.8%.

For the third quarter of 2017, the acquired company BSN medical's organic sales rose by 1.7%. The adjusted EBITA margin for the acquired company was 19.2% and was negatively impacted by approximately 0.4 percentage points as a result of integration costs.


Media and analysts are invited to a press conference, where this interim report will be presented by Magnus Groth, President and CEO.

Time: 10:00 CET, Thursday, October 26, 2017
Location: Essity's headquarters, Waterfront Building, Klarabergsviadukten 63, Stockholm, Sweden

The presentation will be webcasted at www.essity.com . To participate, call: +44 (0)20 7162 0077, +1 646 851 2407 or +46 8 5052 0110. Specify "Essity" or conference ID no. 962907.

For further information, please contact:
Fredrik Rystedt,
CFO and Executive Vice President
+46 8 788 51 31

Johan Karlsson
Vice President Investor Relations
Group Function Communications
+46 8 788 51 30

Joséphine Edwall-Björklund
Senior Vice President
Group Function Communications
+46 8 788 52 34

Media Relations
Group Function Communications
+46 8 788 52 20

This information is such information that Essity Aktiebolag (publ) is obligated to make public pursuant to the EU Market Abuse Regulation. This report has been prepared in both Swedish and English versions. In case of variations in the content between the two versions, the Swedish version shall govern. The information was submitted for publication, through the agency of the contact person set out below, at 08:00 CET on October 26, 2017. This interim report has not been reviewed by the company's auditors.                      

Karl Stoltz, Media Relations Manager, +46 8 788 51 55

This information was brought to you by Cision http://news.cision.com

The following files are available for download:


The full report (PDF)



These press releases may also interest you

at 21:59
LONDON, Nov. 20, 2017 /PRNewswire/ -- Global Plasma Protease C1-inhibitor Treatment Market: OverviewThis report on the plasma protease C1-inhibitors treatment market analyzes the current and future scenario of the global market. Large number of...

at 21:37
LONDON, Nov. 20, 2017 /PRNewswire/ -- Global Ophthalmic Surgical Technologies Market: OverviewThe global ophthalmic surgical technologies market report provides a clear picture of the comprehensive dynamics of the market. The ophthalmic surgical...

at 21:21
LONDON, Nov. 20, 2017 /PRNewswire/ -- "Global tissue diagnostics market projected to grow at a CAGR of 6.9% during the forecast period" Download the full report: https://www.reportbuyer.com/product/5206184The tissue diagnostics market is expected to...

at 21:19
LONDON, Nov. 20, 2017 /PRNewswire/ -- Global Tattoo Removal Devices Market: OverviewThe report on the global tattoo removal devices market offers a critical evaluation of key factors and notable trends influencing the growth of the market. The study...

at 21:18
NEW YORK, Nov. 20, 2017 /PRNewswire/ -- Weight Watchers International, Inc. (NYSE: WTW) (the "Company") announced today that it has priced $300.0 million in aggregate principal amount of its 8.625% senior notes due 2025 (the "Notes") in a private...

at 21:17
LONDON, Nov. 20, 2017 /PRNewswire/ -- Global Stretch Marks Treatment Market: OverviewStretch marks also known as striae are commonly observed during or after pregnancy, during puberty, or a sudden change in weight. These marks appear due to the...

News published on 26 october 2017 at 02:23 and distributed by: